Clinical research on the prevention and treatment of facial scarring
Discussion of Clinical Cases · 17.07.2026 · 11 (3) · 27-34
DOI: 10.5430/dcc.v11n3p27 ↗Kurz gefasst
Fachartikel in der Zeitschrift Discussion of Clinical Cases, online erschienen am 17.07.2026. Verfasst von Zhihui Hou und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Objective
To investigate new approaches to the prevention and treatment of facial scarring by using fractional CO2 laser therapy, platelet-rich plasma (PRP), and a combination of fractional CO2 laser therapy and PRP to treat sutured facial wounds.
Methods
152 patients with facial trauma admitted to the outpatient department of the Plastic Surgery Department at a Grade A tertiary hospital between March 2020 and March 2022 were selected. Using a random number table, the patients were divided into the laser treatment group (n = 50), the PRP treatment group (n = 51), and the combination treatment group (n = 51). All groups received the routine debridement and cosmetic suturing. One week after suture removal, the laser treatment group underwent the laser treatment; the PRP treatment group received PRP microneedling, and the combination treatment group received a combination of fractional CO2 laser therapy and PRP treatment. The efficacy, the level of inflammatory factors, the difference in thickness between the wound site and the normal skin, and the Vancouver Scar Scale (VSS) score were compared among the three groups at baseline, 3 months, 6 months, and 1 year after treatment.
Results
Regarding the efficacy, after 6 months of treatment, the overall response rates for the laser treatment group, the PRP treatment group, and the combination therapy group were 76%, 78.43%, and 94.12%, respectively. The overall response rate in the combination treatment group was higher than that in the laser treatment group and the PRP treatment group; χ2 = 6.923, p = .031, p < .05, indicating statistical significance. After 6 months of treatment, levels of TNF-α, IL-2, and IL-6 were decreased to varying degrees in the laser treatment group, the PRP treatment group, and the combination treatment group. The levels of inflammatory factors in the combination treatment group were lower than those in the PRP treatment group and the laser treatment group (p < .05), indicating a statistical significance; similarly, the levels of inflammatory factors in the PRP treatment group were lower than those in the laser treatment group (p < .05), indicating a statistical significance. Compared with pre-treatment measurements, the thickness of scars relative to normal skin was gradually decreased in the laser treatment group, the PRP treatment group, and the combination treatment group at 3 months, 6 months, and 1 year post-treatment. The difference in thickness between the wound site and normal skin in the combination treatment group was consistently smaller than that in the PRP treatment group and the laser treatment group (p < .05), indicating a statistical significance; The difference in thickness between the wound site and normal skin in the PRP treatment group was consistently smaller than that in the laser treatment group (p < .05), indicating a statistical significance. Compared with pre-treatment levels, VSS scores were decreased in the laser treatment group, the PRP treatment group, and the combination treatment group at 3 months, 6 months, and 1 year post-treatment. The VSS scores in the combination treatment group were lower than those in the PRP treatment group and the laser treatment group (p < .05), indicating statistical significance; similarly, the VSS scores in the PRP treatment group were lower than those in the laser treatment group (p < .05), indicating statistical significance.
Conclusions
The combination of fractional CO2 laser therapy and PRP therapy demonstrates a significant efficacy in preventing and treating facial scars. It reduces inflammation and markedly improves scar color, thickness, and texture, yielding better results than laser therapy or PRP therapy alone.
Zitieren
APA
Hou, Z., Gao, X., & Gu, M. (2026). Clinical research on the prevention and treatment of facial scarring. Discussion of Clinical Cases, 11(3), 27-34. https://doi.org/10.5430/dcc.v11n3p27
Vancouver
Hou Z, Gao X, Gu M. Clinical research on the prevention and treatment of facial scarring. Discussion of Clinical Cases. 2026;11(3):27-34. doi:10.5430/dcc.v11n3p27
BibTeX
@article{Hou2026,
author = {Hou, Zhihui and Gao, Xiang and Gu, Mingjuan},
title = {Clinical research on the prevention and treatment of facial scarring},
journal = {Discussion of Clinical Cases},
year = {2026},
volume = {11},
number = {3},
pages = {27--34},
doi = {10.5430/dcc.v11n3p27}
}
EUVIMED